NCT07781397

Brief Summary

This study evaluates whether a drug-free, non-invasive haptic patch (LIBERTY Patch) affects fall-risk classification and balance/mobility confidence in adults ages 55 to 85. Approximately 150 participants are assigned to wear either the active LIBERTY Patch or a visually identical sham patch daily for 7 days. Balance and mobility are assessed using the FallSkip wearable device and a Falls Efficacy Scale questionnaire at baseline and again after 7 days. Neither participants nor investigators know which patch is assigned during the study period, though this can be unblinded in an emergency.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
150

participants targeted

Target at P75+ for not_applicable

Timeline
3mo left

Started Jun 2025

Geographic Reach
1 country

1 active site

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress83%
Jun 2025Dec 2026

Study Start

First participant enrolled

June 16, 2025

Completed
1.2 years until next milestone

First Submitted

Initial submission to the registry

August 19, 2026

Completed
5 days until next milestone

First Posted

Study publicly available on registry

August 24, 2026

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2026

Last Updated

August 24, 2026

Status Verified

August 1, 2026

Enrollment Period

1.5 years

First QC Date

August 19, 2026

Last Update Submit

August 19, 2026

Conditions

Keywords

SuperPatchLIBERTYHapticVibrotactile Trigger TechnologyVTTfall riskfall preventionaccidental fallsbalancemobilityolder adults

Outcome Measures

Primary Outcomes (2)

  • Change in fall-risk/mobility assessment (FallSkip device)

    A 2-3 minute mobility assessment (sit-to-stand, walking, and return to seated position) using the FallSkip wearable device, comparing Active vs. Control groups.

    Baseline and Day 7

  • Change in Falls Efficacy Scale score

    A 10-item, self-reported scale (adapted from Tinetti et al., 1990) measuring confidence in performing daily activities (bathing, dressing, walking, transferring, etc.) without falling, scored 1 (very confident) to 10 (not confident at all) per item.

    Baseline and Day 7

Secondary Outcomes (1)

  • Incidence of patch-associated sensations/side effects

    Throughout the 7-day study period, assessed at Day 7

Study Arms (2)

Active LIBERTY Patch (Vibrotactile/Haptic)

ACTIVE COMPARATOR

Participants apply the active LIBERTY Patch (Haptic Vibrotactile Trigger Technology) daily for 7 days, with fall-risk/mobility assessment (FallSkip device) and Falls Efficacy Scale survey completed at baseline and Day 7.

Device: LIBERTY Patch

Control (Sham Patch)

SHAM COMPARATOR

Participants apply a visually identical sham patch without active technology daily for 7 days, with the same baseline and Day 7 assessments as the Active arm.

Device: Sham Patch

Interventions

A drug-free, non-invasive, investigational topical patch designed to assist with balance and mobility, worn daily for 7 days.

Also known as: Haptic Vibrotactile Trigger Technology (VTT) Patch
Active LIBERTY Patch (Vibrotactile/Haptic)

A visually identical patch without active technology, worn daily for 7 days under the same conditions as the active patch.

Control (Sham Patch)

Eligibility Criteria

Age55 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Ages 55 to 85, inclusive
  • Able to provide written informed consent
  • Able to walk independently or with assistive devices
  • Lucid, with adequate cognitive ability to consent

You may not qualify if:

  • History of severe neurological disorders (e.g., advanced Parkinson's, severe stroke history)
  • Known allergies to adhesives
  • Currently hospitalized
  • Use of drugs of abuse (illicit or prescription)
  • Severe visual/auditory impairments affecting gait or balance
  • Terminal illness or life expectancy less than 6 months
  • Severe dementia or cognitive impairment preventing consent
  • Ongoing physical therapy specifically targeting balance/gait
  • Post-stroke
  • Pregnant
  • Existing or planned implantation of a pacemaker or other electrical device

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Anna Toker, MD

Mansfield, Texas, 76063, United States

Location

Related Publications (2)

  • Fason J, Hurwitz P, Gudin J. Reducing Pain and Improving Mobility Using Haptic Patch Technology: Results of the RESTORE Study. Pain Ther. 2025 Dec;14(6):1797-1807. doi: 10.1007/s40122-025-00780-0. Epub 2025 Oct 8.

    PMID: 41057672BACKGROUND
  • Tinetti ME, Richman D, Powell L. Falls efficacy as a measure of fear of falling. J Gerontol. 1990 Nov;45(6):P239-43. doi: 10.1093/geronj/45.6.p239.

    PMID: 2229948BACKGROUND

MeSH Terms

Interventions

Transdermal Patch

Intervention Hierarchy (Ancestors)

Equipment and Supplies

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Masking Details
Participants and investigators are masked to patch assignment (active LIBERTY Patch vs. visually identical sham patch) throughout the 7-day study period.
Purpose
PREVENTION
Intervention Model
PARALLEL
Model Details: Participants are assigned to one of two parallel groups. Participants in the Active group apply the LIBERTY Patch (embedded with Haptic Vibrotactile Trigger Technology) daily for 7 days, while participants in the Control group apply a visually identical sham patch daily for 7 days. Both groups complete a fall-risk/mobility assessment using the FallSkip wearable device and the Falls Efficacy Scale questionnaire at baseline and again at Day 7, allowing a between-group comparison of change in fall-risk classification and balance/mobility confidence. Neither participants nor investigators are informed of patch assignment during the 7-day comparison period. After Day 7, participants may optionally continue in the study using the alternate patch, outside the primary comparative endpoint.
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 19, 2026

First Posted

August 24, 2026

Study Start

June 16, 2025

Primary Completion (Estimated)

December 1, 2026

Study Completion (Estimated)

December 1, 2026

Last Updated

August 24, 2026

Record last verified: 2026-08

Data Sharing

IPD Sharing
Will not share

Individual participant data will not be shared. This is a minimal-additional-risk, single-site-network study in an at-risk elderly population (ages 55-85) evaluating an investigational, non-significant-risk device, conducted under a HIPAA Authorization and Advarra IRB oversight. Participant health data are used and disclosed only to the parties specified in the informed consent (the sponsor, Clarity Science, LLC, Advarra IRB, and applicable regulatory authorities) for purposes of conducting this study. Given the population's potential vulnerability (older adults, some with mobility impairment) and the narrow consented scope of data use, de-identified data sharing beyond these parties was not part of the consent framework, consistent with the study's HIPAA Authorization.

Locations